Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $37.08 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Stock Down 2.9 %

NASDAQ HRTX traded down $0.07 during trading hours on Thursday, hitting $2.35. The company's stock had a trading volume of 1,437,551 shares, compared to its average volume of 2,303,241. The stock has a fifty day moving average of $2.17 and a 200 day moving average of $1.80. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The firm has a market capitalization of $357.98 million, a P/E ratio of -13.05 and a beta of 1.39.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HRTX. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.